Stockreport

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

Daxor Corporation  (DXR) 
NASDAQ:AMEX Investor Relations: daxor.com/investors
PDF Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 [Read more]